A systematic review and meta‐analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis‐related hepatocellular carcinoma

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Viral Hepatitis

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jvh.12096PMID 24010648
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses

  2014cited by this paper
• Hepatitis C viral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus

  2013cited by this paper
• 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines

  2012cited by this paper
• Hepatocellular carcinoma

  2012cited by this paper
• Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection

  2012cited by this paper
• Recognizing and preventing death from compensated cirrhosis in the community

  2012cited by this paper
• Long-Term Results of a Randomized, Observation-Controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma After Curative Resection

  2012cited by this paper
• Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

  2011cited by this paper
• Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: A meta‐analysis of randomized controlled trials

  2011cited by this paper
• Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.

  2011cited by this paper
• Interpretation of random effects meta-analyses

  2011cited by this paper
• Hepatocellular Carcinoma: Current Management and Future Development—Improved Outcomes with Surgical Resection

  2011cited by this paper
• Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration

  2011cited by this paper
• Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma

  2011cited by this paper
• Review article: current antiviral therapy of chronic hepatitis B

  2011cited by this paper
• Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials.

  2010cited by this paper
• Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach.

  2010cited by this paper
• Interferon‐α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus‐related hepatocellular carcinoma

  2010cited by this paper
• Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus‐related liver cancer

  2010cited by this paper
• Meta‐analysis: interferon‐alpha prevents the recurrence after curative treatment of hepatitis C virus‐related hepatocellular carcinoma

  2010cited by this paper
• Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis.

  2010cited by this paper
• Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma

  2010cited by this paper
• Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

  2009cited by this paper
• [Postoperative interferon therapy after resection of hepatitis C virus-related hepatocellular carcinoma].

  2008cited by this paper
• Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

  2008cited by this paper
• Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

  2007cited by this paper
• Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis

  2007cited by this paper
• Practical methods for incorporating summary time-to-event data into meta-analysis

  2007cited by this paper
• Long-Term Interferon Maintenance Therapy Improves Survival in Patients with HCV-Related Hepatocellular Carcinoma after Curative Radiofrequency Ablation

  2007cited by this paper
• A Randomized, Controlled Trial of Postoperative Adjuvant Interferon Therapy After Resection of Hepatocellular Carcinoma

  2007cited by this paper
• Uncertainty in heterogeneity estimates in meta-analyses

  2007cited by this paper
• Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.

  2007cited by this paper
• Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis

  2006cited by this paper
• Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.

  2006cited by this paper
• Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial

  2006cited by this paper
• Sustained viral response prolonged survival of patients with C‐viral hepatocellular carcinoma

  2006cited by this paper
• Growth inhibitory effects of pegylated IFN α‐2b on human liver cancer cells in vitro and in vivo

  2006cited by this paper
• Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo.

  2006cited by this paper
• Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma

  2006cited by this paper
• Antiviral therapy after non‐surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus

  2005cited by this paper
• Low-Dose, Long-Term, Intermittent Interferon-alpha-2b Therapy after Radical Treatment by Radiofrequency Ablation Delays Clinical Recurrence in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma

  2005cited by this paper
• Effect of Long-Term Postoperative Interferon Therapy on Intrahepatic Recurrence and Survival Rate after Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma

  2005cited by this paper
• Hepatocellular carcinoma: current surgical management.

  2004cited by this paper
• Surgical treatment of hepatocellular carcinoma: Similar long‐term results despite geographic variations

  2004cited by this paper
• Prospective randomized controlled study of interferon‐alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors

  2004cited by this paper
• Primary liver cancer: worldwide incidence and trends.

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus

  2003cited by this paper
• Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels.

  2002cited by this paper
• Randomized clinical trial of long‐term outcome after resection of hepatitis C virus‐related hepatocellular carcinoma by postoperative interferon therapy

  2002cited by this paper
• Hepatocellular carcinoma: current surgical management.

  2001cited by this paper
• Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study.

  2001cited by this paper
• Effects of Long-Term Postoperative Interferon- Therapy on Intrahepatic Recurrence after Resection of Hepatitis C VirusRelated Hepatocellular Carcinoma

  2001cited by this paper
• Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial.

  2001cited by this paper
• Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer

  2000cited by this paper
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

  1998cited by this paper
• Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

  1996cited by this paper
• Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan.

  1996cited by this paper
• Can determination of the proliferative capacity of the nontumor portion predict the risk of tumor recurrence in the liver remnant after resection of human hepatocellular carcinoma?

  1993cited by this paper
• Hepatocellular carcinoma.

  1986cited by this paper

• Evolving roles of systemic therapy in hepatocellular carcinoma: neoadjuvant and adjuvant strategies

  2025cites this paper
• Treatment options for advanced hepatocellular carcinoma: the potential of biologics

  2024cites this paper
• Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future

  2024cites this paper
• Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis

  2024cites this paper
• Adjuvant treatment strategy after curative resection for hepatocellular carcinoma

  2021cites this paper
• HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management

  2021cites this paper
• Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis

  2021cites this paper
• Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy

  2019cites this paper
• Antiviral Therapy for AECHB and Severe Hepatitis B (Liver Failure)

  2019cites this paper
• Complete cure of a patient with HBV-associated hepatocellular carcinoma with lung metastasis using interferon and survival up to 108 months: A case report and literature review

  2018cites this paper
• Functional characterization of adipocytes in regulation of liver cancer stem cells

  2018cites this paper
• Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity

  2017cites this paper
• Analysis of the time and workers needed to conduct systematic reviews of medical interventions using data from the PROSPERO registry

  2017cites this paper
• Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.

  2017cites this paper
• of CSF-1 R induced tumor infiltration by PMN-MDSC d Combination of CSF-1 R with CXCR 2 inhibitors demonstrated strong anti-tumor effect

  2017cites this paper
• Management of hepatocellular carcinoma: an overview of major findings from meta-analyses

  2016influential citation
• lncRNA in the liver: Prospects for fundamental research and therapy by RNA interference.

  2016cites this paper
• The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.

  2016cites this paper
• Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma.

  2015cites this paper
• Assessment for Risk of Bias in Systematic Reviews and Meta-Analyses in the Field of Hepatology

  2015cites this paper
• Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis

  2015cites this paper
• Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma.

  2015cites this paper
• Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies.

  2014cites this paper
• Reactivation of telomerase reverse transcriptase gene in liver cancer

  2014cites this paper
• Managing hepatitis B to prevent liver cancer: recent advances

  2014cites this paper
• Overview and recent trends of systematic reviews and meta-analyses in hepatology

  2014cites this paper
• Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review

  2014cites this paper
• Postoperative therapy options for hepatocellular carcinoma

  2014cites this paper
• Management of viral hepatitis in patients with hepatocellular carcinoma

  2013cites this paper
• Hepatitis C viral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus

  2013cites this paper
• Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Tumors.

  year unknowncites this paper